BBP ETF — Virtus LifeSci Biotech Products ETF

Virtus LifeSci Biotech Products ETF (BBP)

Updated October 16, 2026.

BBP is an ETF. its expense ratio is 0.34%. Total return is 290.4% over the past 11.8 years, 71.2 points behind SPY at 361.6%.

Virtus LifeSci Biotech Products ETF tracks the performance of U.S.-listed biotechnology companies that have at least one FDA-approved drug therapy on the market. The fund does not currently distribute to shareholders, though it made a special one-time distribution in the past that should not be expected to recur; it carries an expense ratio of 0.34%. This ETF may appeal to investors seeking equity exposure to the biotechnology sector without relying on regular income distributions.

BBP performance versus SPY

Price and return data through 2026-10-16.

Total return is 290.4% over the past 11.8 years, 71.2 points behind SPY at 361.6%. Over the past year its total return — price change plus distributions reinvested — is 38.9%. Its deepest 1-year drawdown was 9.4%.

BBP key facts

Issuer

Virtus Investment Partners

Asset type

ETF

Asset class

Equity

Inception date

12/16/2014

Expense ratio

0.34%

Distribution frequency

None

Last close

$100.20 (as of 2026-10-16)

AUM

$127,063,141

Average volume

30567.0

Ex-dividend date

12/20/2017

Payment date

12/27/2017

Beta

0.73

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Virtus Investment Partners; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BBP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 9.4%.

Who may consider BBP — and who may not

It is a weaker fit for investors who need monthly cash flow (BBP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BBP

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions

More securities from Virtus Investment Partners.